Marizyme, Inc.
(Note: Marizyme, Inc. withdrew its plans for a NASDAQ uplisting from the OTCQB Market and a public offering in an SEC letter dated April 21, 2023. The S-1 was filed Feb. 14, 2022. Under the deal’s most recent terms, Marizyme had planned to offer 1.52 million units (1,523,810 units) at an assumed public offering price […]
February 14, 2022 Read More